Skip to main content
. 2022 Aug 10;187(6):866–877. doi: 10.1111/bjd.21743

Figure 5.

Figure 5

Time to relapse through week 52. Maintenance period, rerandomized maintenance intention‐to‐treat population (OASIS‐1). The time of last dose prior to randomization is week 12. CI, confidence interval; HR, hazard ratio; MIRI, mirikizumab; NA, not applicable; Q8W, every 8 weeks. The numbers of patients at risk in brackets represent the number, of those being assessed, who lost or did not maintain ≥90% improvement in Psoriasis Area and Severity Index. aHR stratified by bodyweight (< 100 kg or ≥ 100 kg). b P‐value (two sided): log‐rank test for comparison with placebo Q8W stratified by bodyweight (< 100 kg or ≥ 100 kg).